Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	7.06M -24.6%
Revenue (ttm)	4.70M +12.8%
Net Income	-28.74M
EPS	-16.38
Shares Out	1.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,317
Open	3.240
Previous Close	3.200
Day's Range	3.202 - 3.780
52-Week Range	3.130 - 7.200
Beta	1.08
Analysts	Buy
Price Target	29.00 (+691.27%)
Earnings Date	Aug 11, 2026

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $29.0, which is an increase of 691.27% from the latest price.

Price Target

$29.0

(691.27% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 22, 2026

Data Sources Report a data error